NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT
Updated: Feb 10
NCT05130827: Phase 2: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
NCT05130827: Phase 2: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant (AHCT).
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborator
ClinicalTrials.gov Identifier: NCT05130827
Official Title: Pilot Trial of Plinabulin and Pegfilgrastim to Reduce the Duration of Absolute Neutropenia After Autologous Hematopoietic Cell Transplantation for Patients With Multiple Myeloma
First Posted : November 23, 2021
Click here for details on ClinicalTrials.gov
Plinabulin (Code C62444)
NPI-2358
Plinabulin
PLINABULIN
Pegfilgrastim (Code C1854)
Filgrastim SD-01
filgrastim-SD/01
Fulphila
HSP-130
Jinyouli
Neulasta
Neulastim
Nyvepria
PEG-filgrastim
Pegcyte
Pegfilgrastim
pegfilgrastim
PEGFILGRASTIM
Pegfilgrastim Biosimilar HSP-130
Pegfilgrastim Biosimilar Nyvepria
Pegfilgrastim Biosimilar Pegcyte
Pegfilgrastim Biosimilar PF-06881894
Pegfilgrastim Biosimilar Udenyca
Pegfilgrastim Biosimilar Ziextenzo
pegfilgrastim-apgf
pegfilgrastim-bmez
pegfilgrastim-cbqv
Pegfilgrastim-jmdb
PF-06881894
SD-01
SD-01 sustained duration G-CSF
Udenyca
Ziextenzo
US brand name:
Fulphila
Neulasta
Nyvepria
Udenyca
Ziextenzo
Foreign brand name:
Jinyouli
Neulastim
Pegcyte
Drug: Plinabulin
Location
United States, New York